

# MAKING DRUGS WORK BETTER: COMBINATION WITH DELIVERY SYSTEMS

Landhaus, Landhausquai 4, CH-4500 Solothurn

Drug-device combination products represent the next wave of drug delivery systems with incredible advantages for patients but are of high complexity in terms of design and development. In this context, the SwAPP has elaborated an Exchange Expertise event for pharma professionals and academics, who are interested to learn more about the way of improving drug efficiency and safety, as well as patient compliance, by integrating the latest medical device technologies.

## Programme

**11:00 SwAPP General Assembly and election of the new Board** (for SwAPP members, guests are welcomed)

**13:00 ExEx Symposium: Reception and Coffee break**

**13:15 Welcome**

*Mirjam Eglin, President, SwAPP (Bern, CH)*

**13:30 Plenary Session**

❖ **Innovation in Drug Delivery: from Energy Activated Drugs to Connected Medical Devices**

*Jakob Lange, Senior Director Delivery Systems, Ypsomed (Bern, CH)*

❖ **Human-centered Design Approach in Development of Drug Delivery Systems**

*Cédric Gysel, Manager Health Care Solutions Design, Johnson & Johnson (Zurich, CH)*

❖ **Challenges in Developing Combination Products**

*Oliver Shergold, Head of Device Technology, Novartis (Basel, CH)*

**15:30 Coffee break**

**16:00 Parallel Breakout Sessions**

<b>N°1 - Regulatory</b>	<b>N°2 - Clinical</b>	<b>N°3 - Innovation</b>
<p><b>Impact of the Medical Device Regulation on Combination Products</b></p> <p>- Doris Penna, Regulatory Affairs Manager, Eli Lilly (Geneva, CH)</p> <p>- Andrea Sparti, Regulatory Affairs Manager, Cendres+Métaux (Biel, CH)</p> <p>- Andreas Balsiger Betts, Senior Advisor, Sidley Austin (Geneva, CH)</p>	<p><b>Clinical Trials of Combination Products vs Drugs: Present and Future</b></p> <p>- Raquel Billiones, Senior Director, Head of Medical Writing, Takeda Vaccines (Zurich, CH)</p> <p>- Olivier Goarnisson, Counsel, Sidley Austin (Geneva, CH)</p> <p>- Frank van den Ouweland, Consultant, Pharmaceutical Medicine (Geneva, CH)</p>	<p><b>Medicinal Product + Medical Device: Technological Challenges &amp; Mutual Understanding</b></p> <p>- Flora Felsovalyi, Principal Device Engineer, Pharma Technical Development Biologics Europe, F. Hoffmann-La Roche (Basel, CH)</p> <p>- Laurent-Dominique Piveteau, CEO, Debiotech (Lausanne, CH)</p> <p>- Oliver Shergold, Head of Device Technology, Novartis (Basel, CH)</p>

**17:00 Parallel Breakout Sessions (repetition)**

**17:55 Concluding remarks**

*Representative of the new Board, SwAPP (Bern, CH)*

**18:00 Closing Networking Apéro**

## Registration

- Please register via “Xing Events”; see [here](#)
- Registration and payment are required prior to the symposium.
- To organise the break between General Assembly and ExEx symposium, and the closing networking apéro, please indicate if you plan to join also the General assembly (without charges) and/or the closing apéro. The participant fee includes break and apéro costs.
- At events, SwAPP is taking photographs and videos of our conferences and courses (both online and in print). By registering for the meeting you agree that you accept the further use of the photographs and/or videos.

## Participation Fees

SwAPP Members	CHF 300,- (Early bird seats available up to Feb, 19th) CHF 400,-
Non-Members	CHF 450,- (Early bird seats available up to Feb, 11th) CHF 550,-
Students (basic studies)	CHF 100,-
Groups, please contact us: <a href="mailto:swapp@swapp.ch">swapp@swapp.ch</a> , re: ExEx 2019 groups	

## Venue

**Landhaus: Landhausquai 4, CH-4500 Solothurn** - The Landhaus is situated in the historical center of Solothurn, directly at the Aare, 550m footway from SBB main station via Hauptbahnhofstrasse, Kreuzackerbrücke.

## Cancellation Policy

You may cancel 10 business days before the meeting and receive a full refund minus the cancellation fee of CHF 50.- Cancellations less than 10 business days before the symposium date will not be refunded.

## Accreditation

This event is accredited with 4.5 credits by SwAPP/ SGPM, and with 35 credits by GSASA for hospital pharmacy.

## Learning Objectives

- To familiarize with some of the latest innovations in the field of drug delivery devices
- To understand how such systems can improve drug efficacy and safety
- To be aware of the challenges to face when integrating delivery devices in drug development
- To become acquainted with some key regulatory requirements of drug-device combination products
- To have a better understanding of both adjacent legislations, including the new EU Medical Device Regulation

## Target Audience

New comers and experienced professionals interested in the development of drug-device combination products, regulatory affairs, clinical affairs, quality, medical affairs, market access, drug formulation, packaging, process development, manufacturing; working in the Industry, Contract Research Organisations, Competent authorities, Notified bodies, Ethics Committees or Academia.

## Patronages

interpharmaph

SWISS MEDTECH

BioAlps  
Life Sciences Cluster Western Switzerland

Swiss Biotech  
Association

SICHI

swiss  
clinical  
trial  
organisation

NETWORK  
in ar ti s  
SWISSLIFESCIENCESCOMMUNITY

vips

GENEVA  
PHARMA  
NETWORK